ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ

ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ
ᱠᱞᱤᱱᱤᱠᱟᱞ ᱰᱮᱴᱟ
ᱵᱮᱯᱟᱨ ᱧᱩᱛᱩᱢᱠᱚ	Myrbetriq, Betanis, Betmiga, others
ᱮᱴᱟᱜ ᱧᱩᱛᱩᱢ	YM-178
ᱮ.ᱮᱭᱤᱪ.ᱮᱯᱷ.ᱮᱥ/ᱰᱨᱟᱜᱥ.ᱠᱚᱢ	Monograph
ᱰᱮᱴᱟ	EU EMA: yes; US FDA: Mirabegron;
ᱦᱚᱲᱢᱚᱜ; ᱛᱷᱚᱠ	AU: B3 ; US: C (Risk not ruled out) ; ;
ᱵᱮᱵᱷᱟᱨ ᱨᱮᱱᱟᱜ; ᱴᱷᱟᱶ	By mouth (tablets)
ᱮ.ᱴᱤ.ᱥᱤ ᱠᱳᱰ	G04BD12 (WHO) ;
ᱟᱹᱱᱟᱹᱨᱤ ᱦᱟᱞᱚᱛ
ᱟᱹᱱᱟᱹᱨᱤ ᱦᱟᱞᱚᱛ	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);
ᱯᱷᱟᱨᱢᱟᱠᱳᱠᱟᱭᱱᱮᱴᱤᱠ ᱰᱮᱴᱟ
ᱵᱟᱭᱳᱭᱮᱵᱷᱮᱞᱮᱵᱷᱮᱞᱤᱴᱤ	29–35%
ᱯᱨᱳᱴᱤᱱ ᱛᱚᱱᱚᱞ	71%
ᱢᱮᱴᱟᱵᱳᱞᱤᱡᱚᱢ	Hepatic via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase
ᱵᱟᱹᱜᱤ ᱟᱫᱷᱟ-ᱡᱤᱭᱚᱱ	50 hours
ᱨᱟᱪᱟᱥᱮᱫ	Urine (55%), faeces (34%)
ᱩᱯᱨᱩᱢᱤᱭᱟᱹ
	ᱟᱭ.ᱭᱩ.ᱯᱤ.ᱮ.ᱥᱤ ᱧᱩᱛᱩᱢ 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide;
ᱥᱤ.ᱮ.ᱮᱥ ᱱᱚᱢᱵᱚᱨ	223673-61-8;
ᱯᱟᱵᱽᱠᱮᱢ ᱥᱤ.ᱟᱭ.ᱰᱤ	9865528;
ᱠᱮᱢᱥᱯᱟᱭᱰᱟᱨ	8041219;
ECHA InfoCard	100.226.392
Chemical and physical data
ᱯᱷᱚᱨᱢᱩᱞᱟ	C21H24N4O2S
ᱢᱤᱞᱟᱨ ᱢᱟᱥ	396.506 g/mol g·mol−1
ᱛᱷᱨᱤᱰᱤ ᱢᱚᱰᱮᱞ (ᱡᱮ.ᱮᱥ.ᱢᱳᱞ)	Interactive image;
	ᱮᱥ.ᱮᱢ.ᱟᱭ.ᱮᱞ.ᱤ.ᱮᱥ O=C(Nc1ccc(cc1)CCNC[C@H](O)c2ccccc2)Cc3nc(sc3)N;
	ᱟᱭ.ᱮᱱ.ᱥᱤ.ᱮᱭᱤᱪ.ᱮᱞ InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1; Key:PBAPPPCECJKMCM-IBGZPJMESA-N;

ᱤᱸᱞᱤᱥ ᱞᱤᱸᱠ

https://or.wikipedia.org/wiki/Mirabegron

ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ(ᱤᱸᱞᱤᱥ ᱯᱟᱹᱨᱥᱤᱛᱮ Mirabegron, ᱢᱤᱫ ᱟᱹᱠᱷᱨᱤᱧ ᱧᱩᱛᱢ ᱢᱤᱨᱵᱮᱴᱨᱤᱠ/ Myrbetriq) ,ᱱᱚᱣᱟ ᱢᱤᱫ ᱨᱟᱱ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱪᱩᱰᱩᱛᱷᱩᱞᱤ ᱛᱤᱠᱪᱷᱟᱹᱨᱮ(overactive bladder) ᱵᱮᱵᱷᱟᱨᱚᱜᱼᱟ।^[᱒] ᱚᱠᱥᱤᱵᱭᱩᱴᱤᱱ (oxybutynin) ᱞᱮᱠᱟ ᱟᱱᱴᱤᱢᱚᱥᱠᱟᱨᱤᱱ ᱨᱟᱱ(antimuscarinic medication) ᱠᱷᱚᱱ ᱠᱚᱢᱜᱮᱠᱚ ᱯᱚᱥᱚᱸᱫᱼᱟ। ^[᱓] ᱱᱚᱣᱟ ᱨᱟᱱ ᱢᱚᱪᱟ ᱨᱮᱠᱚ ᱮᱢᱚᱜᱼᱟ ।^[᱒]

ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ ᱨᱮᱱᱟᱜ ᱚᱨᱥᱚᱝ ᱛᱮ ᱥᱚᱠᱛᱚ ᱢᱟᱭᱟᱢ ᱪᱟᱯ , ᱵᱚᱦᱚᱜ ᱦᱟᱹᱥᱩ, ᱪᱩᱰᱩ ᱱᱟᱞᱟ ᱜᱷᱟᱣ ᱠᱚ ᱦᱩᱭ ᱫᱟᱲᱟ ᱦᱟᱜᱼᱟ ।^[᱒] ᱱᱚᱣᱟ ᱵᱟᱫ ᱠᱟᱛᱮ ᱟᱧᱤᱭᱳᱭᱤᱰᱤᱢᱟ, ᱚᱦᱤᱥᱟᱹᱵ ᱡᱤᱣᱤᱪᱟᱹᱞᱩ irregular heart rate ᱟᱨ ᱭᱩᱨᱤᱱᱟᱨᱤ ᱨᱤᱴᱮᱱᱥᱚᱱ ᱦᱩᱭᱫᱟᱲᱮ ᱦᱟᱜᱼᱟ ।^[᱒]^[᱓] ᱱᱚᱣᱟ ᱵᱤᱴᱟᱼ᱓ ᱟᱰᱨᱮᱱᱡᱤᱠ ᱨᱤᱥᱮᱯᱴᱚᱨᱼᱮ (β₃ adrenergic receptor) ᱪᱮᱸᱜᱷᱟ ᱦᱚᱪᱚ ᱠᱷᱟᱹᱛᱤᱨ ᱪᱩᱰᱩᱛᱷᱩᱞᱤ (bladder) ᱚᱪᱚᱲᱚᱜᱼᱟ । ^[᱓]^[᱒]

ᱰᱟᱠᱛᱚᱨᱤ ᱵᱮᱵᱷᱟᱨ ᱞᱟᱹᱜᱤᱫ ᱒᱐᱑᱒ ᱥᱟᱞ ᱨᱮ ᱭᱩ ᱮᱥ ᱮ ᱱᱚᱣᱟ ᱨᱟᱱ ᱢᱟᱱᱚᱛ ᱮ ᱮᱢ ᱞᱮᱫ ᱛᱟᱦᱮᱸᱫ ।^[᱔]^[᱒] ᱒᱐᱑᱙ ᱥᱟᱞ ᱨᱮ ᱭᱩᱱᱟᱭᱴᱮᱰ ᱠᱤᱝᱰᱚᱢᱨᱮ (United Kingdom) ᱮᱱᱮᱪᱮᱥ (NHS) ᱢᱤᱫ ᱪᱟᱸᱫᱚ ᱨᱮᱱᱟᱜ ᱰᱳᱡ ᱯᱤᱪᱷᱟᱹ ᱒᱙ ᱯᱟᱶᱰ ᱞᱮᱠᱟ ᱠᱷᱚᱨᱚᱪ ᱦᱩᱭ ᱟᱭ ᱠᱟᱱ ᱛᱟᱦᱮᱸᱫ ।^[᱓] ᱭᱩ ᱮᱥ ᱮ ᱨᱮ ᱢᱤᱫ ᱪᱟᱸᱫᱚ ᱨᱮ ᱱᱚᱣᱟ ᱨᱮᱱᱟᱜ ᱦᱳᱞᱥᱮᱞ ᱫᱟᱢ ᱓᱖᱙ ᱟᱢᱮᱨᱤᱠᱟ ᱰᱚᱞᱟᱨ ᱠᱟᱱᱟ ।^[᱕] ᱒᱐᱑᱖ ᱥᱟᱞ ᱨᱮ ᱱᱚᱣᱟ ᱨᱟᱱ ᱑ᱱᱤᱭᱩᱛ ᱠᱷᱚᱱ ᱡᱟᱹᱥᱛᱤ ᱯᱨᱮᱥᱠᱨᱤᱯᱥᱚᱱ ᱞᱮᱱ ᱠᱷᱟᱹᱛᱤᱨ ᱡᱟᱹᱥᱛᱤ ᱯᱨᱮᱥᱠᱨᱤᱯᱥᱚᱱ ᱦᱟᱠᱟᱱ ᱨᱟᱱ ᱨᱮᱱᱟᱜ ᱛᱟᱹᱞᱠᱟᱹᱨᱮ ᱒᱖᱓ ᱟᱱᱟᱜ ᱴᱷᱟᱶ ᱮ ᱟᱢᱮᱴ ᱞᱮᱫᱼᱟ ।^[᱖]

ᱥᱟᱹᱠᱷᱭᱟᱹᱛ

↑ ^᱑.᱐ ^᱑.᱑ ^᱑.᱒ ^᱑.᱓ ^᱑.᱔ "mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 November 2013.
↑ ^᱒.᱐ ^᱒.᱑ ^᱒.᱒ ^᱒.᱓ ^᱒.᱔ ^᱒.᱕ "Mirabegron Monograph for Professionals". Drugs.com (in ᱟᱝᱜᱽᱨᱮᱡᱤ). American Society of Health-System Pharmacists. Retrieved 18 March 2019.
↑ ^᱓.᱐ ^᱓.᱑ ^᱓.᱒ ^᱓.᱓ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 763. ISBN 9780857113382.
↑ Sacco, E; Bientinesi, R; et al. (Apr 2014). "Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence". Expert Opin Drug Discov. 9 (4): 433–48. doi:10.1517/17460441.2014.892923. PMID 24559030.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ᱟᱝᱜᱽᱨᱮᱡᱤ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

ᱵᱟᱦᱨᱮ ᱡᱚᱱᱚᱲ

Sacco, E.; Bientinesi, R. (2012). "Mirabegron: A review of recent data and its prospects in the management of overactive bladder". Therapeutic Advances in Urology. 4 (6): 315–24. doi:10.1177/1756287212457114. PMC 3491758. PMID 23205058.

[MSR-1] ᱑.᱐ ^᱑.᱑ ^᱑.᱒ ^᱑.᱓ ^᱑.᱔ "mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 November 2013.

[AHFS2019-2] ᱒.᱐ ^᱒.᱑ ^᱒.᱒ ^᱒.᱓ ^᱒.᱔ ^᱒.᱕ "Mirabegron Monograph for Professionals". Drugs.com (in ᱟᱝᱜᱽᱨᱮᱡᱤ). American Society of Health-System Pharmacists. Retrieved 18 March 2019.

[BNF76-3] ᱓.᱐ ^᱓.᱑ ^᱓.᱒ ^᱓.᱓ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 763. ISBN 9780857113382.

[4] Sacco, E; Bientinesi, R; et al. (Apr 2014). "Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence". Expert Opin Drug Discov. 9 (4): 433–48. doi:10.1517/17460441.2014.892923. PMID 24559030.

[NADAC2019-5] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ᱟᱝᱜᱽᱨᱮᱡᱤ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[6] "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

[᱑]